Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05754580
Other study ID # 0199-23-FB
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 29, 2023
Est. completion date October 1, 2026

Study information

Verified date October 2023
Source University of Nebraska
Contact Heather D Mittelstedt, RN
Phone 402-559-8287
Email hmittelstedt@unmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR) brachytherapy to the prostate in patients with localized unfavorable-intermediate risk or higher disease.


Description:

Currently the practice of minimizing monetary and human costs of therapy in the field of oncology is in vogue. As such, there has been heightened interest in the ability to decrease the total number and duration of radiation therapy treatments via brachytherapy and stereotactic body radiation therapy (SBRT). With this, the use of SBRT has been increasingly utilized for elective nodal irradiation (ENI) to treat patients with intermediate-risk prostate cancer or higher to improve biochemical progression free survival (bPFS). However, there is a dearth of studies assessing the efficacy and toxicity profile of these two modalities in combination. The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of SBRT to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR) brachytherapy to the prostate in patients with localized unfavorable-intermediate risk or higher disease. We hypothesize that this combination therapy will have an acceptable toxicity profile and that ENI via SBRT will provide improved bPFS compared to no nodal treatment and synonymous with conventional fractionation. The sample size will be 53 patients, with biopsy confirmed unfavorable-intermediate or higher risk prostate cancer and ≥ 15% probability of nodal involvement as determined by publicly available nomograms. Eligible patients will undergo ultrasound-guided HDR brachytherapy to the whole prostate to a dose of 15 Gy in 1 fractions followed by SBRT to a dose of 25 Gy in 5 fractions given every other day. Follow-up will assess toxicity and biochemical progression-free survival and subsequent comparison to historical results.


Recruitment information / eligibility

Status Recruiting
Enrollment 53
Est. completion date October 1, 2026
Est. primary completion date October 1, 2025
Accepts healthy volunteers No
Gender Male
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Histopathologically proven diagnosis of local unfavorable intermediate or higher risk prostate cancer as defined by NCCN risk group criteria. Biopsies will be confirmed by UNMC pathology review if collected outside our institution. 2. No prior definitive treatment or intervention received. 3. Life expectancy of more than 10 years as estimated by the treating physician. 4. Negative evaluation lymph node involvement or distant metastatic disease on abdominopelvic CT, prostate MRI, and/or PSMA PET. 5. Negative evaluation of osseous metastatic disease via bone scan or PSMA PET scan. 6. Greater than or equal to 15% nodal involvement risk predicated on publicly available MSKCC pre-prostatectomy nomogram. 7. Karnofsky performance status = 80 within 30 days prior to registration. 8. Age = 19 years. 9. Clinically determined to be a candidate for HDR brachytherapy. 10. Patient must be able to provide study-specific informed consent prior to study entry. Exclusion Criteria: 1. American Urological Association Urinary Symptom Score (AUA score) = 15. 2. Large prostate volume relative to pelvic arch width that can hinder proper placement of applicator insertion. To be done by MRI, TRUS, and/or physical exam for size, by CT A/P or MRI for arch interference. Specifically, prostates must be no greater than 75 cc in size as decerned by MRI, TRUS, or physical exam. Potential for pubic arch interference will be decerned by the treating radiation oncologist based on MRI and/or CT imaging. 3. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. 4. Relative or absolute contraindications to radiation therapy as determined by the treating physician. These include, but not limited to, inflammatory bowel disease, connective tissue disorders (systemic lupus erythematosus, scleroderma, etc.), genetic disorders that risk increase sensitivity to radiation therapy. 5. Medical conditions that, in the opinion of the investigator could compromise patient safety. 6. Prior invasive malignancy other than prostate cancer (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year. 7. History of rectal surgeries. 8. Recent major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to registration. 9. History of Urolift. 10. Contraindications to general anesthesia. 11. Preexisting rectal fistula.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
High Dose Brachytherapy
This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
Stereostatic Body Radiation Therapy
ultra-hypofractionation radiation therapy.

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (1)

Lead Sponsor Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-Related Adverse Events To evaluate acute GI or GU toxicity and patient reported symptoms outcomes of SBRT and HDR brachytherapy boost as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 with a scale of Grade 1 through Grade 5 with Grade 1 being mild and Grade 5 being death. The International Prostate Symptom Score (IPSS) will also be used with a scale of 1 through 35, with 1-7 being mild, 8-19 being moderate, and 20-35 being severe. And the International Index of Erectile Function Questionnaire. between the start of treatment up to 6 months post-treatment.
Secondary Proportion of patients with reported symptom outcomes of SBRT and HDR brachytherapy To be assessed with the International Prostate Symptom Score (IPSS) with a scale of 0 to 35 with 0-7 being mild, 8-19 being moderate, and 20-35 being severe, and the International Index of Erectile Function (IIEF) with a scale of 5 to 25 with 5 being poor function and 25 indicating no dysfunction. Between the start of treatment and 6 months post-radiation treatment
Secondary Biochemical progression free survival (bPFS) To be assessed using serial measurements of prostate-specific antigen and using the Phoenix definition of biochemical failure (PSA nadir + 2 ng/mL for two separate measurements). Month 4, 10, 16, 22, and 28 post-SBRT
Secondary Proportion of patients with chronic toxicity and side-effects from HDR Brachytherapy and SBRT To be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 with a scale of Grade 1 through Grade 5 with Grade 1 being mild and Grade 5 being death. The International Prostate Symptom Score (IPSS) will also be used with a scale of 1 through 35, with 1-7 being mild, 8-19 being moderate, and 20-35 being severe. And the International Index of Erectile Function Questionnaire. Between 6 months to 28 months post-treatment
Secondary Number of patients with local control (LC), locoregional control (LRC), distant metastasis (DM), and overall survival (OS) To be assessed with physical examinations, diagnostic imaging including CT, PET/CT, and/or MRI in the event of biochemical recurrence. Through study completion, an average of 28 months after treatment
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01086956 - Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy N/A
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02687308 - Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique N/A
Completed NCT01284608 - Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) N/A
Completed NCT04421781 - Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
Recruiting NCT05740956 - A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Not yet recruiting NCT05851521 - To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES) N/A
Completed NCT01998685 - Prothrombotic Factors and Anaesthesia in Prostate Cancer N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Not yet recruiting NCT06439784 - Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy N/A
Terminated NCT03606889 - Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia N/A
Completed NCT03481816 - Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Phase 1
Completed NCT01171729 - Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer Phase 1/Phase 2
Recruiting NCT05623878 - 68Ga-labeled NY108 PET Imaging in Patients Early Phase 1
Not yet recruiting NCT05184790 - LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Completed NCT02564120 - North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)